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study demonstrated that non-adherence to atypical antipsychotics
leads to more hospitalizations and hospital days in the treatment
of schizophrenia.
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OBJECTIVES: To identify which patient baseline characteristics
and which types of early changes in patients’ clinical status are
most predictive of switching antipsychotics in the long-term
treatment of schizophrenia. METHODS: This post-hoc analysis
used data from a randomized, open-label, multi-site, one-year
cost-effectiveness trial of olanzapine, risperidone, and typical
antipsychotics in the treatment of schizophrenia. Study protocol
permitted switching of antipsychotics when clinically warranted.
Baseline characteristics were assessed using standard psychiatric
measures and systematic review of medical records. In addition
to baseline socio-demographics, co-morbid medical and psychi-
atric conditions, body weight, clinical, and functional character-
istics, the prediction model included change scores on clinical
measures (PANSS, ﬁve PANSS factor subscales, Barnes Akathisia
Scale, Simpson Angus Scale) during the ﬁrst two weeks of treat-
ment. Cox proportional hazards model was used to identify the
best predictors of switching from patients’ initial randomized
antipsychotic. RESULTS: About one-third (29.5%, 190/644)
switched antipsychotics before the end of the one-year trial. Five
variables were identiﬁed as best predictors of switching during
the 1-year trial (p < 0.05): absence of antipsychotic use in the
prior year, pre-existing depression, lack of lifetime substance use
disorder, less improvement or worsening following two weeks of
treatment on either clinician-rated akathisia (Barnes Akathisia
Scale), and/or anxiety/depression symptoms (PANSS). A strong
trend was observed for female gender (p = 0.058). CONCLU-
SIONS: Switching of antipsychotics appears to be prevalent in
the naturalistic treatment of schizophrenia, and can be predicted
by a small and distinct set of measures. Interestingly, pre-
existing depressive symptomatology and less improvement or
worsening of anxiety and depressive symptoms following two
weeks of treatment were among the more robust predictors of
future switching of antipsychotics in this one-year study.
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OBJECTIVES: To determine and compare the compliance and
persistence to typical and atypical antipsychotics in the treatment
of schizophrenia patients. METHODS: The study was based on
NC Medicaid claims database. Patients were included if they had
a diagnosis of schizophrenia (ICD-9 295.XX), received at least
two antipsychotic prescriptions during the period after index
date and were continuously enrolled in NC Medicaid Program
during three month prior and one year post treatment periods.
Medication possession ratio (MPR), persistence and medication
use gap were used as compliance measures. Both descriptive and
multivariate model were conducted to determine the difference
in adherence/persistence to antipsychotic medications between
typical and atypical antipsychotic. RESULTS: A total of 919
patients (469 in typical and 450 in atypical) met the selection
criteria for 3-month prior and 12-month after antipsychotic
treatment. There were statistically signiﬁcant differences between
typical and atypical antipsychotics in terms of demographics,
comorbidities, resource utilization in prior period, and adher-
ence. As compared with those in typical groups, patients in atyp-
ical group were signiﬁcantly younger (42.3 vs. 44.4, p = 0.0195),
less blacks (33.1% vs. 58.4%), had more comorbid diseases (2.7
vs. 2.3, p = 0.0025), more hospital visits (0.3 vs. 0.17, p = 0.002)
and greater total costs in prior period ($2703 vs. $2010, p =
0.012). The costs and utilization in prior period indicated that
patients in atypical groups were sicker than those in typical
groups. Patients in atypical group were more adherent to
antipsychotics (35.8% vs. 16.4%, p < 0.0001), less gaps (42.4%
vs. 67%, p < 0.0001), and stayed consistently in medication
longer (229 days vs. 146 days). CONCLUSIONS: The results
from this study indicated that there existed signiﬁcant differences
in terms of demographics, compliance and persistence between
typical and atypical antipsychotics in the treatment of 
schizophrenia.
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OBJECTIVES: To assess the clinical, functional, and economic
ramiﬁcations of switching antipsychotics for any cause during
treatment of schizophrenia. METHODS: We used outpatient
data from a randomized, open-label, one-year cost-effectiveness
trial of olanzapine, risperidone, and typical antipsychotics in the
treatment of schizophrenia. Study protocol permitted switching
of antipsychotics when clinically warranted. Resource utilization
was abstracted from medical records. Treatment outcomes were
assessed with standard psychiatric measures. Changes from pre-
to-post switch were assessed among patients who switched from
randomized antipsychotics. Switchers and non-switchers were
compared on risk for crisis-related events (e.g., hospitalization).
RESULTS: About one-third of the patients (30.2%, 185/612)
were switched from randomized antipsychotics: 14.9% from
olanzapine, 27.9% from risperidone, and 48.5% from typical
antipsychotics. Following antipsychotic switch, switchers expe-
rienced signiﬁcant improvements in symptoms and social rela-
tions (p < 0.001), and numerical cost reductions ($3.72 per day
less, p = 0.320). Compared to non-switchers, switchers were at
signiﬁcantly higher risk for crisis-related events (p = 0.006),
experienced them sooner (p = 0.004), and accrued higher 
crisis-related service costs (p < 0.05). CONCLUSIONS:
Although switching antipsychotics is an effective “rescue”
option, it is costly in personal and economic terms. The optimal
treatment strategy is to begin treatment with the antipsychotic
most likely to lead to effective treatment for each individual
patient.
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OBJECTIVES: To review the literature addressing the economic
consequences of nonadherence in the treatment of schizophre-
nia. This study also seeks to extend the review results to provide
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an update on the economic costs related to nonadherence to
antipsychotics. METHODS: A systematic MEDLINE search for
the years 1995–2004 was conducted to identify published
English-language articles on the economic impact of medication
nonadherence in schizophrenia. A manual search was also per-
formed using the references of retrieved articles to identify addi-
tional studies. For a study to be included, the direct healthcare
costs or the inpatient days related to nonadherence must have
been speciﬁcally assessed or estimated. We extracted data on
nonadherence rate, relapse rate, and inpatient days based on the
identiﬁed studies, and derived the daily hospital costs for schiz-
ophrenia in 2001 from National Inpatient Sample of Healthcare
Cost and Utilization Project. We then extrapolated the data to
national level to obtain an estimate on the inpatient costs related
to nonadherence to antipsychotics. RESULTS: A total of 7
studies were identiﬁed and assessed according to their study
design, measurement of medication nonadherence, study setting,
and cost outcome results. Although adherence measures varied
across studies, all the studies reviewed showed that nonadher-
ence to antipsychotic drugs was related to an increase in hospi-
talization rate, hospital days or hospital costs. Based on the
results from selected studies, we estimated that the national
rehospitalization costs related to nonadherence to antipsychotics
ranged approximately from $609 million to $979 million in year
2001. CONCLUSIONS: There is a consensus in the literature
that poor adherence to antipsychotic medications was associated
with higher risk of relapse and rehopitalization and higher 
hospitalization costs. Future investigations need to search more
effective interventions targeting speciﬁcally to nonadherent
patients to improve patient outcomes and reduce health care
costs.
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OBJECTIVES: To assess the duration of antipsychotic switching
process in the naturalistic treatment of schizophrenia.
METHODS: This post hoc analysis used data from a random-
ized, open-label, one-year trial of olanzapine, risperidone, and
typical antipsychotics in the treatment of schizophrenia (N =
664), in which switching of antipsychotics was permitted, when
clinically warranted. No suggestions were provided to clinicians
as to which switching strategy to use or how long the switch
process should last. The number of overlapping days between
antipsychotics during each switch was calculated for all switch-
ing episodes in the study (N = 217), by antipsychotic type
(typical, atypical), and by speciﬁc atypical antipsychotic (olan-
zapine, risperidone). RESULTS: Most of the switching between
antipsychotics (58.5%) was abrupt, with complete discontinua-
tion of the previous antipsychotic the same day or a day after
the start of the new antipsychotic. Abrupt switching was most
prevalent between the 2 atypical antipsychotics (75.9%), and
least prevalent when switching from any typical to atypical
antipsychotics (47.0%). The next most prevalent switching strat-
egy involved cross titration lasting 1–7 days (16.0%). CON-
CLUSIONS: Abrupt switching appears to be the most prevalent
antipsychotic switching strategy. Abrupt switching was previ-
ously found to provide outcomes comparable to other antipsy-
chotic switching strategies in the treatment of schizophrenia.
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OBJECTIVES: Depression is a prevalent psychiatric disorder
associated with impaired patient functioning and reductions in
health-related quality of life (HRQL). The present study
describes the impact of depression on patients’ HRQL and
assesses the impact of antidepressant treatment on HRQL.
METHODS: A total of 447 patients were recruited at 56 primary
care centres to this naturalistic longitudinal observational study.
Patients over 18 years with depressive symptoms, and who ini-
tiated a new antidepressant therapy were included in the study.
Data on patients’ socio-demographics, daily activity and quality-
of-life (EQ-5D) were collected using questionnaires completed
during outpatient GP visits for a follow-up period of 6 months.
Disease severity was assessed with the Clinical Global Impres-
sion Severity scale (CGI-S). Regression analysis was employed to
analyse the determinants of quality-of-life in depressed patients.
RESULTS: The mean EQ-5D utility score at baseline was 0.47
(0.44–0.49). Milder cases of depression reported a health utility
of 0.60, whereas moderately and severely depressed patients
reported utility values of 0.46 and 0.27 respectively (p < 0.001).
At end of follow-up the average utility in the sample was 0.69
(0.67–0.72), corresponding to an increase in utility by 0.23 over
6 months (p < 0.001). Our regression model showed that, all else
equal, patients who were on sickleave were associated with 10%
lower utility (p < 0.0001). Moreover, increased disease severity
(assessed with CGI) was associated with decreased health-related
quality of life. By treating the patient to achieve clinical remis-
sion is associated with higher quality of life and the presence 
of co-morbidity is associated with decreased quality-of-life.
CONCLUSIONS: Depression has a substantial impact on
health-related quality of life of the patient. Our results indicate
that antidepressants are associated with signiﬁcant improvement
in EQ-5D index score over a course of 6 months. Self-reported
patient valuations are important outcomes for cost-effectiveness
analysis of new antidepressant compounds.
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Despite the increased focus over the past decade suggesting that
full remission should be the primary goal of the treatment of
depression, there are few studies investigating the health eco-
nomic consequences of attaining remission in pharmacological
treatment in clinical practice. OBJECTIVE: The aim of this study
was to determine what impact full remission has on the cost and
health-related quality-of-life of depressed patients. METHODS:
Longitudinal data on patients’ socio-demographics, daily activ-
ity, health care resource use, quality-of-life (EQ-5D) were col-
lected using questionnaires completed during outpatient GP visit
for a follow-up period of approximately 6 months. Patient
recruitment and data collection were performed at about 56
primary care centres in Sweden and 447 patients were enrolled.
